Compound class:
Synthetic organic
Comment: YCT529 is an oral retinoic acid receptor alpha (RAR-α) antagonist, that is being investigated as a non-hormonal male contraceptive. Its development and function were presented at the spring meeting of the American Chemical Society (ACS) in March 2022. Antagonising RAR-α disrupts spermatogenesis. YCT529 is formulated as a sodium salt. The RAR-α-selective antagonists BMS-189532 and BMS-189614 have been reported previously [1-2].
|
|
References |
1. Chung SS, Cuellar RA, Wang X, Reczek PR, Georg GI, Wolgemuth DJ. (2013)
Pharmacological activity of retinoic acid receptor alpha-selective antagonists in vitro and in vivo.. ACS Med Chem Lett, 4 (5): 446-450. [PMID:24040487] |
2. Noman MAA, Kyzer JL, Chung SSW, Wolgemuth DJ, Georg GI. (2020)
Retinoic acid receptor antagonists for male contraception: current status†. Biol Reprod, 103 (2): 390-399. [PMID:32671394] |